GT Biopharma, Inc.
Develops TriKE® immunotherapies engaging NK cells to treat hematologic and solid tumor cancers.
GTBP | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 505 MONTGOMERY STREET, 94111 SAN FRANCISCO
- Website:
- https://www.gtbiopharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
GT Biopharma, Inc. is a clinical-stage immuno-oncology company focused on developing innovative therapies for cancer. The company utilizes its proprietary Tri-specific Killer Engager (TriKE®) platform technology to create novel biopharmaceuticals. TriKE® therapeutic agents are designed to harness the patient's immune system by simultaneously engaging Natural Killer (NK) cells and specific antigens on cancer cells, facilitating the targeted destruction of malignant cells. GT Biopharma's product pipeline is aimed at treating various hematologic malignancies and solid tumors, such as acute myeloid leukemia and non-Hodgkin's lymphoma.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all GT Biopharma, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GT Biopharma, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GT Biopharma, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
